124 related articles for article (PubMed ID: 2400805)
1. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.
Blaise D; Olive D; Stoppa AM; Viens P; Pourreau C; Lopez M; Attal M; Jasmin C; Monges G; Mawas C
Blood; 1990 Sep; 76(6):1092-7. PubMed ID: 2400805
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Cochran K; Cameron C; Wang E; Schow PW; Daley JF; Ritz J
Blood; 1992 Jan; 79(2):517-26. PubMed ID: 1730094
[TBL] [Abstract][Full Text] [Related]
3. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
Blaise D; Viens P; Olive D; Stoppa AM; Gabert J; Pourreau CN; Attal M; Gaspard MH; Mannoni P; Jasmin C
Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015
[TBL] [Abstract][Full Text] [Related]
5. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.
Fefer A; Robinson N; Benyunes MC; Bensinger WI; Press O; Thompson JA; Lindgren C
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S48-53. PubMed ID: 9457394
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Bosserman L; Murray C; Cochran K; Daley J; Ritz J
Blood; 1990 May; 75(10):2076-84. PubMed ID: 1970938
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study.
Weisdorf DJ; Anderson PM; Blazar BR; Uckun FM; Kersey JH; Ramsay NK
Transplantation; 1993 Jan; 55(1):61-6. PubMed ID: 8420066
[TBL] [Abstract][Full Text] [Related]
9. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy.
Gottlieb DJ; Prentice HG; Heslop HE; Bello-Fernandez C; Bianchi AC; Galazka AR; Brenner MK
Blood; 1989 Nov; 74(7):2335-42. PubMed ID: 2804369
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Higuchi CM; Thompson JA; Petersen FB; Buckner CD; Fefer A
Blood; 1991 Jun; 77(12):2561-8. PubMed ID: 2043762
[TBL] [Abstract][Full Text] [Related]
12. Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation.
Katsanis E; Anderson PM; Filipovich AH; Hasz DE; Rich ML; Loeffler CM; Ochoa AC; Weisdorf DJ
Blood; 1991 Sep; 78(5):1286-91. PubMed ID: 1831682
[TBL] [Abstract][Full Text] [Related]
13. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
Weiss L; Nusair S; Reich S; Sidi H; Slavin S
Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
[TBL] [Abstract][Full Text] [Related]
14. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.
Ackerstein A; Kedar E; Slavin S
Blood; 1991 Sep; 78(5):1212-5. PubMed ID: 1878588
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.
Maraninchi D; Vey N; Viens P; Stoppa AM; Archimbaud E; Attal M; Baume D; Bouabdallah R; Demeoq F; Fleury J; Michallet M; Olive D; Reiffers J; Sainty D; Tabilio A; Tiberghien P; Brandely M; Hercend T; Blaise D
Leuk Lymphoma; 1998 Oct; 31(3-4):343-9. PubMed ID: 9869198
[TBL] [Abstract][Full Text] [Related]
16. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
17. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
18. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
19. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
20. Natural killer (NK) and T cell-associated surface marker expression following allogeneic and autologous bone marrow transplantation (BMT).
Nagler A; Rabinowitz R; Rosengolts-Rat J; Condiotti R; Schlesinger M
J Hematother Stem Cell Res; 2000 Feb; 9(1):63-75. PubMed ID: 10738973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]